Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Adil Daud(Memorial Sloan Kettering Cancer Center), Michael D. Rosenblum
Cited by 526
Related Papers
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
|Journal of Clinical Oncology|2016|674